The Value Meal: How to Save $1,700 Per Month or More on Lapatinib
- 10 August 2007
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (23), 3397-3398
- https://doi.org/10.1200/jco.2007.12.0758
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Prescribing oral chemotherapyBMJ, 2007
- Lapatinib plus Capecitabine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine, 2006
- Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic CarcinomasJournal of Clinical Oncology, 2005
- A PROSPECTIVE, RANDOMIZED STUDY OF COADMINISTRATION OF KETOCONAZOLE AND CYCLOSPORINE A IN KIDNEY TRANSPLANT RECIPIENTS: TEN-YEAR FOLLOW-UPTransplantation, 2004
- Sirolimus and ketoconazole co-prescription in renal transplant recipientsTransplantation, 2004
- Effects of Food on the Clinical Pharmacokinetics of Anticancer AgentsClinical Pharmacokinetics, 2004
- Coadministration of tacrolimus and ketoconazole in renal transplant recipients: cost analysis and review of metabolic effectsTransplantation Proceedings, 2003
- On the assessment of effects of food on the pharmacokinetics of drugs in early developmentBiopharmaceutics & Drug Disposition, 2002
- Dear Doctor: We Really Are Not Sure What Dose of Capecitabine You Should Prescribe for Your PatientJournal of Clinical Oncology, 2002
- Oral chemotherapy: rationale and future directions.Journal of Clinical Oncology, 1998